The solid oral pharmaceutical compositions containing S1P-agonist or pharmaceutically acceptable salts thereof, process for its preparation and method of treatment and reduce the frequency of clinical exacerbations MULTIPLE SCLEROSIS

摘要

1. A solid oral pharmaceutical composition (solid oral dosage form) for the treatment of relapsing-remitting multiple sclerosis and to decrease the frequency of clinical exacerbations of disease and reduce the risk of the progression of disability in relapsing-remitting multiple sclerosis, suitable for oral administration comprising a therapeutically effective amount of a receptor agonist S1P (sphingosine-1-phosphate) and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable my medium does not contain microcrystalline cellulose, sugar alcohol and croscarmellose (carboxymethylcellulose), or pharmaceutically acceptable derivatives kroskarmellozy.2. Solid oral pharmaceutical formulation (solid oral dosage form) according to claim 1, wherein the S1P receptor agonist is 2-amino-2- (2- (4-octylphenyl) ethyl) propane-1,3-diol (fingolimod ) of formula (I) or a pharmaceutically acceptable sol.3. Solid oral pharmaceutical formulation (solid oral dosage form) according to claim 2, characterized in that the pharmaceutically acceptable salt of 2-amino-2- (2- (4-octylphenyl) ethyl) proian-1,3-diol (fingolimod) is a gidrohlorid.4 fingolimod. Solid oral pharmaceutical formulation (solid oral dosage form) according to claim 1, characterized in that the pharmaceutically acceptable carrier comprises starch or a pharmaceutically acceptable proizvodnye.5. Solid oral pharmaceutical formulation (solid oral dosage form) according to claim 4, distinguished